Compare FTAI Aviation Ltd (FTAI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Merck & Co., Inc. — how do they compare? FTAI Aviation Ltd trades at $169.97 (market cap $17.57B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 20× FTAI Aviation Ltd's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 23 Days and Merck & Co., Inc. for 98 Days on average.
| FTAI | MRK | |
|---|---|---|
Market Cap | $17.57B | $351.28B |
Volume | 1,905,014 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $310.04 | $156.43 |
52-Week Low | $152.80 | $82.49 |
Typical Hold Time | 23 Days | 98 Days |
Enterprise Value | $20.69B | $398.04B |
Dividend Yield | 1.17% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $171.06, down 2.16% amid a bearish technical signal, with support at $169 and resistance at $173. The company reported strong 2025 revenue of $2.51B and net income of $501M, though recent quarters have missed EPS estimates. Recent developments include a $500M share buyback program and a 5-year Asia-Pacific maintenance deal with GMF, signaling strategic growth initiatives.
The outlook is mixed: robust analyst consensus (100% buy ratings, $321.25 price target) and shareholder-friendly actions support upside, but consecutive earnings misses, negative operating cash flow, and high valuation ratios (P/E 37.35) pose risks. Investors should weigh growth in aerospace segments against execution challenges and macroeconomic headwinds.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
